Avidity Biosciences reports wider-than-expected Q3 net loss

Avidity Biosciences

10/11/2025 21:20

Overview

Avidity reports Q3 net loss, missing analyst expectations

Strong cash position of $1.9 bln to fund operations to mid-2028

Outlook

Avidity plans BLA submission for del-zota in 2026

Merger with Novartis expected to close in H1 2026

54-week topline data for del-desiran expected in H2 2026

Result Drivers

R&D EXPENSES - Increased R&D expenses due to advancement of clinical programs and higher personnel costs

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Collaboration Revenue
$12.48 mln
Q3 Net Income
Miss
-$174.44 mln
-$149.39 mln (11 Analysts)
Q3 Basic EPS
-$1.27
Q3 Operating Expenses
$201.28 mln
Q3 Operating Income
-$188.81 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 5 "strong buy" or "buy", 10 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy."

Wall Street's median 12-month price target for Avidity Biosciences Inc is $72.00, about 3% above its November 7 closing price of $69.84

Press Release: ID:nPn8f472wa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)